top of page

GPCR News 

Post: Blog2_Post

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Updated: Aug 23, 2022

March 2022


"February 17, 2022 08:00 AM Eastern Standard Time

SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships."


2 views0 comments

Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin